HOME >> BIOLOGY >> NEWS
From a lowly yeast, researchers divine a clue to human disease

MADISON --Working with a common form of brewer's yeast, University of Wisconsin-Madison researchers have uncovered novel functions of a key protein that allow it to act as a master regulatory switch -- a control that determines gene activity and that, when malfunctioning in humans, may contribute to serious neurological disorders.

The work, published in the Dec. 8 issue of the journal Molecular Cell, shows how a mutation in a single gene can have widespread effects on regulation of the genetic program in a cell, causing some genes to be read more than normal and others less than normal.

While nearly every cell in an organism contains a complete set of DNA, each individual cell uses only a small fraction of that information at any given moment, explains David Brow, the senior author of the new study and a professor of biomolecular chemistry in the UW School of Medicine and Public Health. A host of proteins are responsible for controlling which genetic messages are read and how much of the information is used. Working with yeast, Brow and his colleagues show that a protein called Sen1 plays an important early role in this process.

Mutations in the human version of Sen1 are linked to neurological diseases, including a rare form of amyotrophic lateral sclerosis, also known as ALS or Lou Gehrig's disease, and movement disorders. By exploring how Sen1 works in yeast, Brow provides a powerful tool other researchers can use to better understand the interplay of the protein and gene regulation in human disease.

"This work gives a method to start examining what the defect is in humans," he says.

In the past, says Brow, researchers looked at regulation of individual genes but not the whole genome at once. Using yeast, a small and relatively simple organism, the Wisconsin group developed a method to get a broad view of how Sen1 works and what happens when it doesn't work properly.

Normally, Sen1 acts like a molecular
'"/>

Contact: David Brow
dabrow@wisc.edu
608-262-1475
University of Wisconsin-Madison
7-Dec-2006


Page: 1 2

Related biology news :

1. Human proteins evolving slowly thanks to multitasking genes
2. Tibetan antelope slowly recovering, WCS says
3. Walk slowly for weight loss, according to University of Colorado study
4. Vitamin extends life in yeast, Dartmouth Medical School researchers find
5. Food additive inhibits longevity enzyme in yeast, increases cell toxicity, new study finds
6. Examination of internal wiring of yeast, worm, and fly reveals conserved circuits
7. For yeast, a DNA break ensures sex switch for a grandchild
8. Innovative tagging technique may help researchers better protect fish stocks
9. Penn researchers discover how key protein stops inflammation
10. ASU researchers partner with UOP to make biofuel for military jets a reality
11. Einstein researchers prototype vaccine could provide improved protection against tuberculosis

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: From lowly yeast researchers divine clue human disease

(Date:7/23/2015)... (NASDAQ: AWRE ), a leading supplier of biometrics software ... ended June 30, 2015.  Revenue for the ... 33% compared to $6.8 million in the same quarter last ... $0.3 million, or $0.01 per diluted share, which compared to ... period a year ago.  Lower revenue and ...
(Date:7/21/2015)... Passwords have proven futile for securing ... U.S. Office of Personnel Management breach. Biometric authentication ... but developers and end-users are concerned about how ... Biometrics-as-a-Service provider HYPR Corp. announced today the general ... party integration. A video overview ...
(Date:7/9/2015)... 9, 2015  Synaptics Inc. (NASDAQ: SYNA ), a ... it will report financial results for the fourth quarter ... after the close of market. The company will host ... 2:00 p.m. PT (5:00 p.m. ET), during which management ... on the live call, analysts and investors should dial ...
Breaking Biology News(10 mins):Aware, Inc. Reports Second Quarter 2015 Financial Results 2Aware, Inc. Reports Second Quarter 2015 Financial Results 3Aware, Inc. Reports Second Quarter 2015 Financial Results 4Aware, Inc. Reports Second Quarter 2015 Financial Results 5Aware, Inc. Reports Second Quarter 2015 Financial Results 6HYPR Corp. Launches Industry First Biometric Tokenization Platform 2HYPR Corp. Launches Industry First Biometric Tokenization Platform 3HYPR Corp. Launches Industry First Biometric Tokenization Platform 4Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2
(Date:7/30/2015)... ... July 31, 2015 , ... Ralco is honored to announce ... Lyon County Fair to be held August 5-9 in Marshall. The Ralco Enrichment Center ... come from and how agriculture impacts their daily lives. This unique exhibit also features ...
(Date:7/30/2015)... Washington , July 30, 2015 ... Market, by Product (Software, Molecular Modeling, PB/PK, PKPD, Trial ... Discovery & Development, Preclinical, Clinical Trial), by End Users ... Biosimulation Market is expected to reach USD 2,107.99 million ... a CAGR of 15.29%. Browse more ...
(Date:7/30/2015)... 2015 Ascendis Pharma A/S (Nasdaq: ... innovative TransCon technology to address significant unmet medical ... six-month Phase 2 study to evaluate the safety ... 53 treatment-naïve, pre-pubertal children with growth hormone deficiency, ... with the top-line results from our Phase 2 ...
(Date:7/29/2015)... 2015 Sanofi, a global ... second quarter of 2015. CEO Olivier Brandicourt ... performance in different businesses. Watch video ... Topics covered in the interview ... - Performance drivers - Diabetes ...
Breaking Biology Technology:Ralco Announces Primary Sponsorship of Ralco Enrichment Center at Lyon County Fair 2Biosimulation Market Worth 2,107.99 Million USD by 2020 2Biosimulation Market Worth 2,107.99 Million USD by 2020 3Biosimulation Market Worth 2,107.99 Million USD by 2020 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7
Cached News: